AMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to AMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022

Jefferies Reiterates Buy Rating on Amgen (AMGN) as Lumakras Phase III CB200 Hits

August 31, 2022 8:29 AM EDT

Jefferies analyst Michael Yee reiterated a Buy rating and $295.00 price target on Amgen (NASDAQ: AMGN) after Lumakras Phase III CB200 hits, which he said is "good enough."

The analyst commented, "AMGN announced the Lumakras Phase III CB-200 study was positive although mostly... More